Cargando…
The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer
Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Carol Davila University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/ https://www.ncbi.nlm.nih.gov/pubmed/32025249 http://dx.doi.org/10.25122/jml-2019-0115 |